AMRN - アマリン (Amarin Corporation plc) アマリン



symbol AMRN
会社名 Amarin Corp Plc (アマリン)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アマリン(Amarin Corporation plc)は心血管疾患の治療を中心とする脂質科学の専門知識を持つ後期臨床試験段階のバイオ医薬品会社。同社の製品候補「AMR101」は超高純度オメガ3脂肪酸である。同社はトリグリセリド値の高い患者または高トリグリセリド血症患者を治療するための薬品「AMR101」を開発している。平成23年9月、同社は米国食品医薬品局(FDA)に新薬承認申請(NDA)を提出した。平成23年12月、同社は「REDUCE-IT」というタイトルが付けられた「AMR101」の心血管成果試験(イコサペンタエン酸(EPA)及び心血管事故の減少という介入試験)での患者への投薬を開始した。   アマリンは英国のバイオ医薬品メ―カ―。循環器疾患の治療に焦点を当てた治療薬の研究、開発、商業化に従事。主力製品の「Vascepa」カプセルは、重度の高トリグリセリド血症の成人患者向けの治療薬で、米国食品医薬品局(FDA)の承認を取得。エイコサベンタエン酸のエチルエステルを高純度で含む。本社はアイルランド。   Amarin is a rapidly growing, innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From its scientific research foundation to its focus on clinical trials, and now its commercial expansion, it is evolving and growing. In 2009, Amarin had fewer than twenty employees. Today, with offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, and Zug in Switzerland, Amarin has approximately 1,000 employees and commercial partners and suppliers around the world. It is committed to rethinking cardiovascular risk through the advancement of scientific understanding of the impact on society of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management.
本社所在地 2 Pembroke House Upper Pembroke Street 28-32 Dublin Ballsbridge 2 IRL
代表者氏名 Lars G. Ekman ラース・エックマン
代表者役職名 Independent Chairman of the Board
電話番号 +353 1-669-9020
設立年月日 32568
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 241人
adr_tso 291562458
EBITDA EBITDA(百万ドル) -69.12400
終値(lastsale) 18.9
時価総額(marketcap) 5510530456.2
時価総額 時価総額(百万ドル) 5215.741
売上高 売上高(百万ドル) 197.78800
企業価値(EV) 企業価値(EV)(百万ドル) 5254.872
当期純利益 当期純利益(百万ドル) -84.19700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Amarin Corporation plc (ADR) revenues increased 21% to $96.6M. Net loss increased 69% to $58.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Selling/General/Admin. Expense increase of 43% to $71.7M (expense) Co-promotion fees increase from $5.2M to $19.4M (expense).



   Investing in Amarin Corporation plc (AMRN) might be an excellent idea, but the stock is currently overvalued/undervalued  2022/09/06 12:32:00 US Post News
As of Friday, Amarin Corporation plc’s (NASDAQ:AMRN) stock closed at $1.21, up from $1.17 the previous day. While Amarin Corporation plc has overperformed by 3.42%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AMRN fell by -77.59%, with highs and lows ranging from $5.52 to $1.09, […]
   12-Month Price Target For Amarin Corporation plc (NASDAQ:AMRN) Now Sits At $9.00  2022/09/02 11:00:00 Marketing Sentinel
In last trading session, Amarin Corporation plc (NASDAQ:AMRN) saw 8.36 million shares changing hands with its beta currently measuring 1.84. Company’s recent per share price level of $1.17 trading at -$0.01 or -0.85% at ring of the bell on the day assigns it a market valuation of $482.93M. That closing price of AMRN’s stock is … 12-Month Price Target For Amarin Corporation plc (NASDAQ:AMRN) Now Sits At $9.00 Read More »
   Amarin Corporation plc : Amarin to Present at H.C. Wainwright’s 24th Annual Global Investment Conference  2022/08/30 13:00:00 Investegate
1:00 PM: Amarin to Present at H.C. Wainwright’s 24th Annual Global Investment Conference
   Amarin to Present at H.C. Wainwright’s 24th Annual Global Investment Conference  2022/08/30 12:00:00 GlobeNewswire
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022.
   Amarin Corporation plc: New REDUCE-IT Data Show VASCEPA/VAZKEPA (icosapent ethyl) Reduced Cardiovascular Events in Patients Who Are Current or Former Smokers  2022/08/28 09:53:00 Finanz Nachrichten
-- Data Show VASCEPA/VAZKEPA Significantly Reduced First and Total Cardiovascular Events in Combined Current and Former Smokers by 23% and 29% Respectively Relative to Placebo in a Post Hoc Analysi…
   Why Amarin Stock Is Sinking Today  2022/07/01 15:40:33 The Motley Fool
Investors continue to process disappointing data that was published on Thursday.
   AMRN stock in focus after latest data on Vascepa (NASDAQ:AMRN)  2022/06/30 20:34:32 Seeking Alpha
Commercial-stage biotech Amarin Corporation (AMRN) announced on Thursday that serum samples of patients treated with its heart disease drug icosapent ethyl ((IPE)) had only…
   AMRN stock drops after concerns over cardiovascular therapy (NASDAQ:AMRN)  2022/06/30 17:40:32 Seeking Alpha
The shares of commercial-stage biotech Amarin Corporation (AMRN) dropped sharply on Thursday after Stat News raised concerns over the effectiveness of its heart disease…
   Amarin Corporation plc (AMRN) Has Great Growth Outlook For 2022  2022/06/29 11:00:00 Marketing Sentinel
Amarin Corporation plc (NASDAQ:AMRN) has a beta value of 1.81 and has seen 2.15 million shares traded in the last trading session. The company, currently valued at $761.20M, closed the last trade at $1.85 per share which meant it lost -$0.07 on the day or -3.65% during that session. The AMRN stock price is -222.7% … Amarin Corporation plc (AMRN) Has Great Growth Outlook For 2022 Read More »
   Amarin Corporation plc (NASDAQ: AMRN) Stock Seems Like A Good Option  2022/06/24 12:00:00 Stocks Register
Amarin Corporation plc (NASDAQ:AMRN) shares, rose in value on Thursday, 06/23/22, with the stock price up by 5.85% to the previous day’s close as strong demand from buyers drove the stock to $1.99. Actively observing the price movement in the last trading, the stock closed the session at $1.88, falling within a range of $1.875 … Amarin Corporation plc (NASDAQ: AMRN) Stock Seems Like A Good Option Read More »
   Pharma company Amarin has a key asset and a big decision. How Sarissa Capital can help it move forward  2022/01/29 13:45:55 CNBC
Activist fund Sarissa brings extensive knowledge and deep contacts in the health-care space, which could come in handy at Amarin.
   Amarin (AMRN) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference  2022/01/12 21:12:29 Seeking Alpha
   Amarin Corporation plc (AMRN) Fell Out Of Favor With Hedge Funds?  2022/01/12 17:11:18 Insider Monkey
As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade.
   Amarin Corporation plc (AMRN) CEO Karim Mikhail Presents at 40th Annual J.P. Morgan Healthcare Conference (Transcript)  2022/01/11 16:37:02 Seeking Alpha
   Amarin sees Q4 and FY21 revenue below consensus; shares down 3% (NASDAQ:AMRN)  2022/01/10 12:57:04 Seeking Alpha
Amarin (AMRN) provides a business update, including preliminary full-year 2021 revenue results. Q4 and FY 2021 total net revenues are estimated to be ~$140M (consensus $156.02M)

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アマリン AMRN Amarin Corporation plc)

 twitter  (公式ツイッターやCEOツイッターなど)